Close this search box.

Liver Ablative Radiotherapy utilizing Kilovoltage intrafraction monitoring (KIM)

Stereotactic Ablative Body Radiotherapy (SABR) is an established treatment for both primary and secondary liver malignancies and is a highly effective treatment, but precise dose delivery is challenging due to organ motion. Currently, there is a lack of widely available options for performing real-time tumour localisation to assist with accurate delivery of liver SABR. This study will provide an assessment of the impact of Kilovoltage Intrafraction Monitoring (KIM) as a potential solution for real-time image guidance in liver SABR. It is hoped that this information will improve cancer targeting accuracy and lead to better patient outcomes in the future.

Primary Sponsor

University of Sydney

Collaborating Groups

TROG Cancer Research

Accrual Target


Closing Date of Accrual

11 December 2023

Trial Chairperson

Dr Yoo Young (Dominique) Lee, Princess Alexandra Hospital, QLD
Dr Tim Wang, Crown Princess Mary Cancer Centre, Westmead, NSW

Trial Contact

Clinical Trial Registration

Related Post

18 October, 2022

NINJA Radiation Therapy Trial participant tells his journey to treatment

The journey to becoming the 200th participant for the

6 September, 2022

The gift that kept on giving

The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing